NEWS
LATEST
FULL LIST
-
NIH Launches Nation’s First Dedicated Organoid Development Center
The National Institutes of Health (NIH) has announced the creation of the nation’s first dedicated organoid development center, marking a pivotal step in reducing reliance on animal models for biomedical research. The new Standardized Organoid Modeling (SOM) Center, located at the Frederick National Laboratory for Cancer Research, will receive $87 million over the next three…
-
CUTISS Secures CHF 56 Million Series C to Advance Phase 3 Skin-Tissue Therapy
Swiss TechBio company CUTISS has closed a CHF 56 million (≈USD 62 million) Series C financing round, bringing its total funds raised to over CHF 125 million. The new capital will support the ongoing Phase 3 trials of its personalized, bio-engineered skin graft denovoSkin™, and prepare for commercial launch. The round was co-led by the…
-
Prellis Biologics and Eli Lilly Sign Multi-Target Antibody Discovery Agreement
Prellis Biologics has entered into a multi-target drug discovery and development collaboration with Eli Lilly and Company. The agreement combines Prellis’ organoid-based antibody discovery technology with Lilly’s research and commercialization capabilities to develop next-generation human antibody therapeutics. Financial terms were not disclosed, though Prellis stated it will receive an upfront payment, potential development and sales…
-
Humacyte Reports Positive Data on Bioengineered Vessels for Vascular Repair and Coronary Bypass
Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company focused on creating universally implantable bioengineered human tissues, recently announced two notable scientific publications highlighting the potential of its acellular tissue–engineered vessel (ATEV™) platform in both clinical and preclinical settings. Together, these updates underscore Humacyte’s progress in advancing biofabricated vascular grafts from trauma care into cardiovascular surgery. Symvess…
-
eGenesis Wins FDA Green Light for Gene-Edited Pig Kidney Trial
Massachusetts-based biotech eGenesis has received a key FDA clearance to launch a landmark clinical trial testing EGEN-2784, a multiplex gene-edited pig kidney designed for human transplantation. The investigational new drug (IND) approval enables a combined Phase 1/2/3 study that will evaluate the organ’s safety and performance in patients with end-stage kidney disease (ESKD) over a…
-
Terumo Acquires OrganOx for $1.5 Billion: A Landmark Deal in Organ Preservation and Transplantation
Terumo Corporation has announced a $1.5 billion acquisition of OrganOx Limited, a University of Oxford spin-out and global leader in organ preservation devices. The move marks Terumo’s formal entry into the organ transplantation space, an area of growing medical and commercial importance as healthcare systems worldwide grapple with organ shortages and increasing transplantation demand. OrganOx’s…
-
TISSIUM’s COAPTIUM Connect ushers in photopolymer 3‑D printing for implantables
The FDA’s recent De Novo authorization of COAPTIUM Connect removes a long‑standing barrier for photopolymer 3‑D‑printed implants. Developed by Paris‑ and Cambridge‑based TISSIUM and produced on a bespoke printing line co‑engineered with 3D Systems, the fully bioabsorbable sleeve offers an atraumatic, suture‑free method for coupling severed peripheral nerves. U.S. commercial launch began on 23 July 2025, marking the first…
-
Xeltis Reports Positive 24-Month Clinical Success for Regenerative CABG Conduit
Xeltis, a medtech innovator headquartered in The Netherlands, continues to advance the frontier of regenerative cardiovascular implants with new clinical data supporting its Xabg coronary artery bypass conduit. The company announced encouraging results from a European feasibility study, showing both positive safety and patency outcomes in patients undergoing CABG surgery. This builds upon a prior…
-
Aspect Biosystems Showcases Bioprinted Adrenal Tissue Data at ENDO 2025
At the 2025 annual meeting of the Endocrine Society (ENDO) in San Francisco, Aspect Biosystems unveiled compelling preclinical data demonstrating the therapeutic potential of its adrenal Bioprinted Tissue Therapeutics (BTTs) a novel cell therapy approach aimed at restoring hormone function in patients with primary adrenal insufficiency (PAI). The data, presented through both oral and poster…
-
CollPlant Expands U.S. Footprint with Strategic Hire to Lead Commercial GrowthBusiness of Biofabrication
CollPlant Biotechnologies (NASDAQ: CLGN), a leader in recombinant human collagen (rhCollagen) innovation, has appointed Bowman Bagley as Vice President, Commercial North America. The newly created position underscores CollPlant’s growing commitment to scaling its regenerative medicine and bioprinting platforms across the U.S. and Canadian markets. Leadership with Deep Roots in Biomaterials Bagley, an experienced executive in…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 